IL264309A - Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension - Google Patents

Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension

Info

Publication number
IL264309A
IL264309A IL264309A IL26430919A IL264309A IL 264309 A IL264309 A IL 264309A IL 264309 A IL264309 A IL 264309A IL 26430919 A IL26430919 A IL 26430919A IL 264309 A IL264309 A IL 264309A
Authority
IL
Israel
Prior art keywords
grem1
gremlin
antibodies
methods
arterial hypertension
Prior art date
Application number
IL264309A
Other languages
English (en)
Hebrew (he)
Inventor
Dan Chalothorn
Lori C Morton
Original Assignee
Regeneron Pharma
Dan Chalothorn
Lori C Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Dan Chalothorn, Lori C Morton filed Critical Regeneron Pharma
Publication of IL264309A publication Critical patent/IL264309A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL264309A 2016-08-29 2019-01-17 Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension IL264309A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380562P 2016-08-29 2016-08-29
PCT/US2017/048137 WO2018044640A1 (en) 2016-08-29 2017-08-23 Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
IL264309A true IL264309A (en) 2019-02-28

Family

ID=59791160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264309A IL264309A (en) 2016-08-29 2019-01-17 Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension

Country Status (12)

Country Link
US (1) US20180057580A1 (enExample)
EP (1) EP3504238A1 (enExample)
JP (1) JP2019529371A (enExample)
KR (1) KR20190040320A (enExample)
CN (1) CN109641954A (enExample)
AU (1) AU2017320989A1 (enExample)
CA (1) CA3031783A1 (enExample)
EA (1) EA201990613A1 (enExample)
IL (1) IL264309A (enExample)
MA (1) MA46046A (enExample)
MX (1) MX2019002382A (enExample)
WO (1) WO2018044640A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
MX2022016403A (es) 2020-06-18 2023-04-11 Regeneron Pharma Formulaciones de anticuerpo de activina a y métodos para utilizarlas.
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体
AU2023258146A1 (en) * 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
WO2024258870A2 (en) 2023-06-12 2024-12-19 Amgen Inc. Lymphotoxin beta receptor agonist binding proteins
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US9610356B2 (en) * 2011-12-12 2017-04-04 Pieris Pharmaceutical GmbH Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
JP6400479B2 (ja) * 2012-10-29 2018-10-03 株式会社カルディオ 肺疾患特異的治療剤
KR20150129718A (ko) * 2013-03-14 2015-11-20 리제너론 파아마슈티컬스, 인크. Ｇｒｅｍ 1에 대한 인간 항체

Also Published As

Publication number Publication date
KR20190040320A (ko) 2019-04-17
MA46046A (fr) 2019-07-03
WO2018044640A1 (en) 2018-03-08
US20180057580A1 (en) 2018-03-01
MX2019002382A (es) 2019-06-20
CA3031783A1 (en) 2018-03-08
CN109641954A (zh) 2019-04-16
AU2017320989A9 (en) 2019-07-11
AU2017320989A1 (en) 2019-02-07
EA201990613A1 (ru) 2019-07-31
EP3504238A1 (en) 2019-07-03
JP2019529371A (ja) 2019-10-17

Similar Documents

Publication Publication Date Title
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
ZA202003695B (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
IL265800A (en) Anti-lag-3 antibodies and methods of using them
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
IL265439A (en) Antibodies against signal-regulatory alpha protein and methods of use
IL264211A (en) Multispecific antigen binding proteins and methods of using them
SG10201912879YA (en) Anti-sirp-alpha antibodies and methods of use thereof
IL261666A (en) Related proteins and methods of using them
IL264309A (en) Antibodies against Gremlin 1 (grem1) and methods of their use for the treatment of pulmonary hypertension
SI3618863T1 (sl) Protitelesa proti tigitu in načini uporabe njih
IL263818A (en) Antibodies against Zika virus and methods of use
SG10201912563XA (en) Anti-tim-3 antibodies and methods of use thereof
PT3496739T (pt) Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar
ZA201706323B (en) Anti-pvrig antibodies and methods of use
SG10201912984WA (en) Antibodies and methods of use thereof
IL265957A (en) Anti-c1s antibodies and methods of using them
SG11201708220RA (en) Anti-sortilin antibodies and methods of use thereof
IL259681A (en) New antibodies against claudin and methods of using them
IL258627B (en) Anti-htra1 antibodies and methods of using them
SG11202003980PA (en) Anti-apoc3 antibodies and methods of use thereof
IL274376A (en) Antibodies and methods of use
GB201506380D0 (en) Materials and methods for treatment of pulmonary hypertension
GB201416570D0 (en) Materials and methods for treatment of pulmonary arterial hypertenion
GB201321237D0 (en) Materials and methods for treatment of pulmonary arterial hypertension